Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-11-14T18:17:53+00:00

The Dimerix Limited Clinical Trials – ACTION for Diabetic Kidney Disease and ACTION for Focal Segmental Glomerulosclerosis – Are Now Open!

Click Here For More Information

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Research

Our lead program DMX-200 is advancing through Phase 2 trials in patients with Chronic Kidney Disease (CKD).

Learn More

Technology

Our Receptor Heteromer Investigation Technology (Receptor-HIT) has been used by global pharmaceutical partners, and supported the development of our own DMX-200 program.

Learn More

Investors

Access the latest company news and information

Visit Investor Centre

Recent news and media

ASX: Dimerix Awarded $50,000 Innovation Connections Grant

More information available here

ASX: Dimerix Doses First Patient In DMX-200 Clinical Trial For Focal Segmental Glomerulosclerosis (FSGS)

More information here.

ASX: Dimerix Receives Orphan Drug Designation In The European Union For DMX-200 In FSGS

  Read the release here.

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation

Home
Company
Program
Technology
Investors
Contact

© Copyright 2018 Dimerix | Credits

subscribe to patient updates

subscribe to news updates